Trade Desk Option Alert: Jan 16 $72.5 Puts at the Bid: 660 vs 254 OI

Trade Desk Option Alert: Jan 16 $72.5 Puts at the Bid: 660 @ $11.3 vs 254 OI; Ref=$74.56

Trade Desk Option Alert: Jun 20 $80 Puts Sweep (17) near the Ask: 852 vs 576 OI

Trade Desk Option Alert: Jun 20 $80 Puts Sweep (17) near the Ask: 852 @ $9.151 vs 576 OI; Ref=$77.87

Trade Desk Option Alert: Jan, 2027 $120 Calls at the Bid: 1000 vs 513 OI

Trade Desk Option Alert: Jan, 2027 $120 Calls at the Bid: 1000 @ $11.1 vs 513 OI; Ref=$77.9401

Trade Desk Option Alert: Sep 19 $135 Puts at the Ask: 99 vs 130 OI

Trade Desk Option Alert: Sep 19 $135 Puts at the Ask: 99 @ $56.0 vs 130 OI; Ref=$79.015

Trade Desk Option Alert: Sep 19 $90 Calls at the Ask: 600 vs 22 OI

Trade Desk Option Alert: Sep 19 $90 Calls at the Ask: 600 @ $10.7 vs 22 OI; Ref=$81.97

Trade Desk Option Alert: Jan, 2027 $85 Calls at the Bid: 480 vs 37 OI

Trade Desk Option Alert: Jan, 2027 $85 Calls at the Bid: 480 @ $23.15 vs 37 OI; Ref=$81.13

Trade Desk (NASDAQ:TTD) 주식

Trade Desk

The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on devices like computers, smartphones, and connected TVs. It uses data in an iterative manner to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry, and it generates revenue from fees based on a percentage of what its clients spend on advertising.

Scott Bessent Has ‘Worst Job In The World Today:’ Black Swan Author

Equities

News

Global

Markets

TSLA

수요일(2일)로 예정된 관세 발표를 앞두고 시장 전문가들이 잠재적인 경제적 여파를 경고하는 가운데, 몇몇 공화당 상원의원들이 도널드 트럼프 대통령이 캐나다에 25% 관세를 부과하는 것에 반대하는 민주당에 합류할 태세를 보이고 있다.

공화당 상원의원들, 25% 캐나다 관세는 &#34;엄청난 실수&#34; 지적...일부는 민주당 결의안에 합류

The,Red,Crashing,Market,Volatility,Of,Crypto,Trading,With,Technical

DECK

MRVL

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

SPDR S&amp;P 500(NYSE:SPY) 펀드가 추종하는 S&amp;P 500 지수는 37년 만에 글로벌 시장 대비 최악의 분기 성과를 기록했다. 미국 벤치마크 S&amp;P 500 지수는 1988년 이후 가장 큰 폭으로 미국을 제외한 MSCI 전 세계 지수보다 뒤처졌다. 

S&amp;P 500, 1988년 이후 글로벌 시장 대비 최악의 분기 실적 낸 이유는?

Coinbase Photo by Useacoin on Shutterstock

Large Cap

Movers

Trading Ideas

AAPL

ADBE

COIN

EXPE

GMAB

HOOD

IBKR

SAIL

이들 대형 주식은 지난주에 최악의 성과를 보였다. 이 주식이 당신의 포트폴리오에 있나요? 1. 테라다인(NASDAQ:TER)의 주가가 20.08% 하락했다. 이 회사는 포토닉 IC 테스트 회사인 퀀티파이 포토닉스(Quantifi Photonics)를 비공개 금액에 인수하기로 합의했다. 애널리스트들은 이 회사의 가격 전망을 하향 조정했다.

코인베이스, 애플, 로빈후드 등 지난주 급락한 대형주 12종목 (3월 10일-3월 14일)

The Trade Desk, Inc. - Class A Common Stock

The Trade Desk Inc

TDK Corp

Red River Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRBI#NASDAQ">RRBI</a>) reported quarterly earnings of $1.52 per share which beat the analyst consensus estimate of $1.26 by 20.63 percent. This is a 31.03 percent increase over earnings of $1.16 per share from the same period last year. The company reported quarterly sales of $29.88 million which beat the analyst consensus estimate of $23.16 million by 29.00 percent. This is a 13.66 percent increase over sales of $26.29 million the same period last year.

Earnings

Earnings Beats

RRBI

Red River Bancshares Q1 EPS $1.52 Beats $1.26 Estimate, Sales $29.88M Beat $23.16M Estimate

D. Boral Capital analyst Jason Kolbert maintains VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $5 price target.

Price Target

Analyst Ratings

VNRX

D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target

HC Wainwright &amp; Co. analyst Robert Burns downgrades SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) from Buy to Neutral and lowers the price target from $74 to $47.

Downgrades

SWTX

HC Wainwright & Co. Downgrades SpringWorks Therapeutics to Neutral, Lowers Price Target to $47

Americans spooked by headlines about Social Security's shaky finances are <a href="https://www.benzinga.com/personal-finance/25/04/45034325/americans-rush-to-claim-social-security-early-amid-growing-fears-of-cuts-and-agency-instability-under-trump-administration">racing to file claims</a> at 62, even though experts say the math still favors patience.
What To Know: The program's trustees warn that the retirement trust fund could run <a href="https://www.ssa.gov/policy/trust-funds-summary.html">dry by 2033</a>, after which only 79 percent of scheduled benefits would be paid. Yet financial planners argue that grabbing smaller checks today can backfire if you live into your 80s or 90s.
Fear is real: 64 percent of adults now <a href="https://www.allianzlife.com/about/newsroom/2025-Press-Releases/Americans-Are-More-Worried-About-Running-Out-of-Money-Than-Death?utm_source=chatgpt.com">worry more</a> about outliving their money than dying, with Social Security shortfalls ranking just behind inflation as the top stressor, according to a study by Allianz Life. Benefits replace only about 40 percent of <a href="https://www.ssa.gov/policy/docs/ssb/v68n2/v68n2p1.html">preretirement income</a> on average, and agency <a href="https://www.benzinga.com/news/25/04/44999167/social-security-payments-could-face-interruptions-in-may-warns-former-commissioner-martin-omalley-ne">staffing cuts</a> and long wait times have eroded public confidence.
See also: <a href="https://www.benzinga.com/markets/25/04/45091467/trump-can-either-have-his-cake-or-eat-it-economist-justin-wolfers-calls-out-presidents-fundamental-incoherence-on-trade-deals-and-tariffs">Trump Can Either Have His Cake Or Eat It, Economist Justin Wolfers Calls Out President&#8217;s &#8216;Fundamental Incoherence&#8217; On Trade Deals And Tariffs</a>
Still, the incentives to delay are sizable. Claiming at 62 trims monthly checks by <a href="https://www.ssa.gov/benefits/retirement/planner/agereduction.html">roughly 25 percent</a> for those whose full retirement age (FRA) is 66 and by 30 percent for an FRA of 67. Most retirees take the hit anyway, <a href="https://crsreports.congress.gov/product/pdf/R/R44670/14">according</a> to the Congressional Research Service. Waiting past FRA boosts benefits 8 percent per year until age 70 — a 24 percent to 32 percent jump that insures against <a href="https://www.ssa.gov/benefits/retirement/planner/delayret.html">longevity risk</a>.
Delaying is especially valuable for married couples and anyone worried about future inflation shocks, Vanguard researchers <a href="https://corporate.vanguard.com/content/dam/corp/research/pdf/claiming_social_security_early_spectrum_breakeven_longevity_risks.pdf">find</a>. Meanwhile, Donald Trump has repeated that he "won't cut current retirees' benefits," <a href="https://www.benzinga.com/government/25/04/45064937/donald-trump-threatens-to-veto-any-gop-bill-that-touches-medicaid-or-social-security-if-it-cuts-it-i-would-not-approve">reassuring older voters</a> even as Congress debates new taxes or modest trims for younger workers.
Bottom line, planners say: unless poor health shortens your horizon, every month you wait buys larger lifetime protection — and that may matter more than beating Washington's next funding fix.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/tech/25/04/45096452/mark-zuckerberg-denies-tilt-towards-donald-trump-says-big-tech-must-work-with-whoever-is-in-power-describes-last-decade-as-painful-maturation-process">Mark Zuckerberg Denies Tilt Towards Donald Trump, Says Big Tech Must Work With &#8216;Whoever&#8217; Is In Power, Describes Last Decade As &#8216;Painful Maturation Process&#8217;</a>

Personal Finance

Social Security Panic Is Premature, Experts Say: Delaying Claims Still Yields Bigger Checks Despite 2033 Trust-Fund Clock

Graham Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHC#NYSE">GHC</a>) reported quarterly earnings of $11.64 per share which beat the analyst consensus estimate of $11.29 by 3.1 percent. This is a 3.56 percent increase over earnings of $11.24 per share from the same period last year. The company reported quarterly sales of $1.17 billion which missed the analyst consensus estimate of $1.20 billion by 2.73 percent. This is a 1.12 percent increase over sales of $1.15 billion the same period last year.

Earnings Misses

Graham Hldgs Q1 Adj. EPS $11.64 Beats $11.29 Estimate, Sales $1.17B Miss $1.20B Estimate

Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) reported downbeat first-quarter 2025 <a href="https://www.benzinga.com/quote/SPOT/earnings">financial results on Tuesday</a>.
Spotify reported quarterly earnings of $1.13 per share, which missed the analyst consensus estimate of $2.33. The company reported quarterly sales of $4.41 billion (4.19 billion euros), up by 15% year-on-year, which beat the analyst consensus estimate of $4.20 billion.
Spotify clocked monthly average user (MAU) net additions of 3 million quarter-over-quarter to 678 million, which is in line with the guidance.
Spotify said it expects fiscal second-quarter 2025 revenue of $4.52 billion (4.3 billion euros) versus an analyst consensus estimate of $4.39 billion and total MAUs of 689 million.
Spotify shares fell 3.5% to close at $576.94 on Tuesday.
These analysts made changes to their price targets on Spotify following earnings announcement.
<ul>
<li>Rosenblatt analyst Barton Crockett maintained Spotify Technology with a Neutral rating and lowered the price target from $658 to $657.</li>
<li>Evercore ISI Group analyst Mark Mahaney maintained the stock with an Outperform rating and lowered the price target from $700 to $650.</li>
</ul>
Considering buying SPOT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="585" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30083810/image-234-1024x585.png" alt="" class="wp-image-894854" style="width:562px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30083810/image-234-1024x585.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30083810/image-234-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30083810/image-234-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30083810/image-234.png 1113w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

SPOT

Spotify Analysts Slash Their Forecasts After Q1 Earnings

WIIM

Tradeweb Markets shares are trading higher. The company reported Q1 financial results.

Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) will report its second-quarter earnings on Wednesday. As the company reports after market hours, Wall Street expects $2.81 in EPS and <a href="https://www.benzinga.com/topic/semiconductors">$10.65 billion in revenues</a>.
The stock is down 11.44% over the past year, 4.40% YTD. Despite the decline, Qualcomm stock has been an outperformer in the chip sector so far this year. The iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) is down over 15% YTD while the VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) is down 14%.
Wednesday's post-close earnings will put that momentum to the test. Beyond the headline numbers, Wall Street is laser-focused on two flashpoints: the potential impact of renewed Trump-era tariffs and any hints about Apple Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) <a href="https://benzinga.com/etfs/specialty-etfs/25/02/43888012/apples-in-house-modem-chip-sparks-qualcomm-concerns-3-etfs-with-key-exposure">expected phase-out of Qualcomm's modem chips</a>.
Let&#8217;s examine the charts for Qualcomm stock and how it currently compares to Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/25/04/45006138/smarter-cars-ahead-visteon-qualcomm-unveil-ai-cockpit-system">Visteon, Qualcomm Unveil AI Cockpit System For Smart Cars</a>
<h2 class="wp-block-heading">QCOM Stock Chart Mixed Ahead Of Q2 Earnings</h2>
Qualcomm stock is treading water ahead of earnings, with technical indicators painting a mixed picture for investors.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0430"><img loading="lazy" decoding="async" width="627" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30064138/Screenshot-2025-04-30-at-4.10.36-PM.png" alt="" class="wp-image-894586" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30064138/Screenshot-2025-04-30-at-4.10.36-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30064138/Screenshot-2025-04-30-at-4.10.36-PM-300x234.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0430">Chart created using Benzinga Pro</a>
Qualcomm stock, at $146.88, is showing slight selling pressure and a relatively stagnant trend. However, short-term momentum leans bullish, with Qualcomm trading above its eight-day and 20-day simple moving averages ($142.78 and $140.07, respectively). This positioning typically suggests underlying strength and potential for a near-term move higher.
That said, medium- to longer-term signals flash caution. Qualcomm stock is still below its 50-day simple moving average of $151.38 and well beneath its 200-day simple moving average of $163.63 &#8211; both bearish indicators that imply resistance and a broader downtrend. 
The Moving Average Convergence Divergence (MACD) sits at a negative 1.61, reinforcing the bearish undertone, while the Relative Strength Index (RSI) at 52.22 signals a neutral stance, suggesting QCOM stock is neither overbought nor oversold. 
For investors, this setup suggests cautious optimism in the short term, but a clearer breakout or breakdown post-earnings could be needed to set the tone for what's next.
<h2 class="wp-block-heading">Qualcomm Analysts See Over 10% Upside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/QCOM/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Qualcomm stock stands at a Buy currently with a price target of $193.41 a share. The latest analyst ratings from JPMorgan, Citigroup and TD Cowen imply a 10.39% upside for QCOM stock.
Price Action: Qualcomm stock closed the trading day Tuesday at $146.88, down 0.50%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/25/04/45094345/as-chinas-manufacturing-contracts-beijing-releases-defiant-video-calling-us-a-paper-tiger-and-vows-to-never-kneel-to-trumps-trade-war">As China&#8217;s Manufacturing Contracts, Beijing Releases Defiant Video Calling US A &#8216;Paper Tiger&#8217;</a></li>
</ul>
Image: Shutterstock

Technicals

Previews

Tech

QCOM

Qualcomm Stock Momentum Faces A Midweek Stress Test — Apple, Tariffs To Blame?

Pershing Square Holdco, L.P. ("Pershing Square"), the parent holding company of Pershing Square Capital Management, L.P. ("PSCM"), today announced that PSCM has further extended the term of its standstill agreement with Howard Hughes Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HHH#NYSE">HHH</a>) ("HHH") to facilitate ongoing discussions regarding the proposal previously announced by Pershing Square on February 18, 2025 and potential alternatives. On April 29, 2025, the term of the standstill agreement was extended from 5:00 p.m. (Eastern Time) on April 30, 2025 to 5:00 p.m. (Eastern Time) on May 30, 2025.

PSCM Extends Term Of Standstill Agreement With Howard Hughes Holdings To Facilitate Ongoing Discussions On Previous Proposal By Pershing Square And Potential Alternatives

Biotech

General

Oncocyte Announces Trial Progress, Completes Trial Design And Receives IRB Approval; Says Within Coming Weeks It Expects To Welcome Three Transplant Centers As Trial Participants

Better Choice Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#NYSE">BTTR</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRXH#NYSE">SRXH</a>) ("Better Choice" or the "Company"), a leading global health and wellness company, today announced completing its name change to SRx Health Solutions Inc. and the start of trading under the new ticker symbol ‘SRXH' today, Wednesday, April 30, 2025. The Company will continue trading on the NYSE American stock market under the new symbol, and no action is needed by current shareholders.
This name and ticker change follows the successful closing of the business combination between Better Choice Company and SRx Health, pursuant to which the combined company will emerge as a leading global health and wellness company committed to delivering better products and solutions for pets, people, and families.

BTTR

SRXH

Better Choice Company Announces Completion Of Name Change To SRx Health Solutions; Begins Trading Under The Ticker Symbol SRXH Today, Wednesday, April 30, 2025

Humana shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

Equitable Holdings shares are trading lower following a Q1 adjusted EPS miss.

JTAI

Jet.AI Signs LOI With Consensus Core To Pursue Development Of Two Hyperscale Data-Center Campuses

Western Digital shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results and issued Q4 adjusted EPS guidance above estimates. Additionally, the company declared a quarterly dividend of $0.10 per share.

NBIS

DDN Partners With Nebius To Deliver Seamless Performance For Enterprise AI Workloads

CLRB

CLRB stock has given up its prior gain. Cellectar Biosciences shares were trading higher after the company announced a plan to explore strategic alternatives.

<ul>
<li>Final marketing authorization decision for early-stage breast cancer is expected upon the FDA's approval of&nbsp;IceCure's post-market study plan</li>
<li>IceCure to engage with potential clinical sites, breast surgeons and radiologists for the post-market study including at the upcoming American Society of Breast Surgeons (ASBrS) Annual Meeting</li>
<li>ProSense&#xAE; would become the first-in-class minimally invasive choice—a major advancement in women's health and a new paradigm in breast cancer care as a simple out-patient procedure</li>
<li>U.S. sales and distribution team ready to drive sales of&nbsp;ProSense&#xAE; systems and disposable probes—supporting medical community and patients looking for a new minimally invasive option to lumpectomy</li>
</ul>
<a href="https://icecure-medical.com/">IceCure Medical Ltd.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it concluded a productive meeting with the leadership of the U.S. Food and Drug Administration's ("FDA") Center for Devices and Radiological Health ("CDRH") regarding the Company's De Novo marketing authorization request for ProSense&#xAE; in the treatment of early-stage low risk breast cancer when combined with adjuvant endocrine therapy for women aged 70 and over which represents approximately 46,000 patients annually in the U.S.
During the meeting, the FDA requested that IceCure conduct a study after marketing authorization has been granted ("the post-market study"), with the aim of producing additional data in this indication. IceCure will present its post-market study plan, which is expected to include a minimum of 400 patients at 25 sites, to the FDA, and upon the CDRH's approval of such plan, the FDA's final marketing authorization decision is expected.
IceCure is now working diligently on the plan of the post-market study which IceCure plans to submit in approximately a few weeks. The Company is in the process of recruiting clinical sites and doctors across the U.S., including at the American Society of Breast Surgeons (ASBrS) Annual Meeting which takes place April 30 – May 4, 2025. The Company believes this post-market study will support accelerated market adoption of ProSense&#xAE; in early-stage breast cancer.
"This is a very positive development, and we are pleased to have had such a positive discussion with the FDA's CDRH leadership so that women aged 70 and over across America can have access to a minimally invasive option for early-stage breast cancer with ProSense&#xAE;," stated Eyal Shamir, IceCure's Chief Executive Officer. "We are laser focused on the plan of our post-market study and look forward to finalizing it following deep engagement with the leading breast surgeons and radiologists in the U.S., including at ASBrS this week. As such, the meeting with the FDA is very well timed. We look forward to the FDA's approval of our post-market study plan and final marketing authorization decision for ProSense&#xAE; in this indication. Our U.S. sales team is ready for commercialization."

ICCM

IceCure Medical  Announces Meeting With Leadership Of The U.S. Food And Drug Administration's Center For Devices And Radiological Health Regarding The Company's De Novo Marketing Authorization Request For Prosense In The Treatment of Early-Stage Low Risk Breast Cancer When Combined With Adjuvant Endocrine Therapy For Women Aged 70

Benchmark analyst Cody Acree upgrades Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) from Hold to Buy and announces $95 price target.

Upgrades

QRVO

Benchmark Upgrades Qorvo to Buy, Announces $95 Price Target

D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) with a Buy and maintains $17 price target.

IMUX

D. Boral Capital Maintains Buy on Immunic, Maintains $17 Price Target

Press Releases

TTD Deadline: Rosen Law Firm Urges The Trade Desk, Inc. (NASDAQ: TTD) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Investors who lost money on The Trade Desk, Inc.(TTD) should contact The Gross Law Firm about pending Class Action - TTD

TTD Investors Have Opportunity to Lead The Trade Desk, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Legal

DEADLINE ALERT for STZ, TTD, and IBTA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

DEADLINE TONIGHT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Trade Desk

TTD DEADLINE TODAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages The Trade Desk, Inc. Investors to Secure Counsel Before Important April 21 Deadline in Securities Class Action – TTD

The Trade Desk, Inc. Class Action: Levi & Korsinsky Reminds The Trade Desk Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 21, 2025 – TTD

TRADE DESK ALERT: Bragar Eagel & Squire, P.C. is Investigating The Trade Desk, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
02:44 PMFeb 20, 2025	PUT	$72.50	Jan 16, 2026	260	701	660	276	254	TRADE	BEARISH
01:50 PMFeb 19, 2025	PUT	$80.00	Jun 20, 2025	50	27	852	5	576	SWEEP	BEARISH
01:36 PMFeb 19, 2025	CALL	$120.00	Jan 15, 2027	624	36	1000	7	513	TRADE	BEARISH
09:36 AMFeb 18, 2025	PUT	$135.00	Sep 19, 2025	141	0	99	0	130	TRADE	BEARISH
02:23 PMFeb 13, 2025	CALL	$90.00	Sep 19, 2025	141	751	600	3414	22	TRADE	BULLISH
01:05 PMFeb 13, 2025	CALL	$85.00	Jan 15, 2027	624	730	480	1973	37	TRADE	NEUTRAL

Comments

Trade Desk

Unusual Options Activity for

뉴스

파트너 / 기고자

벤징가 글로벌